BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

HRS-7535: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shandong Suncadia Medicine Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Shandong Suncadia Medicine Co., Ltd.NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and ObesityAdults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesirecruiting225

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-05-29P3Shandong Suncadia Medicine Co., Ltd.NCT06589765 A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminType 2 Diabetescompleted810

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.